Table 5. Prevalence percentages and odds ratios for primary outcome (death or loss-to-follow-up) from the logistic regression analysis.
Bivariate Analysis | Multivariate Analysis | ||||
Alive and still in follow-up (N = 8615) | Negative outcomes: death, lost to follow up (N = 1798) | OR (95% C.I.) | OR (95% C.I). | p-value | |
Age: Mean (SD) | 35.9 (8.0) | 36.0 (8.5) | - | - | 0.980 |
Sex: male | 59.1 | 69.2 | 1.55 (1.39–1.73) | 1.42 (1.21–1.65) | <0.001 |
Alcoholism: yes | 26.0 | 30.5 | 1.25 (1.11–1.40) | 0.98 (0.84–1.15) | 0.804 |
Literate | 90.5 | 88.1 | 0.78 (0.66–0.91) | 0.68 (0.56–0.83) | <0.001 |
Prior history of ART | 25.1 | 18.6 | 0.68 (0.60–0.78) | 0.73 (0.58–0.90) | 0.004 |
WHO Stage III/IV at baseline | 71.4 | 87.5 | 2.81 (2.43–3.26) | 2.36 (1.90–2.94) | <0.001 |
Underweight (BMI <18.5) | 44.7 | 68.3 | 2.66 (2.37–3.00) | 1.97 (1.71–2.26) | <0.001 |
CD4 at baseline <100 | 42.9 | 62.6 | 2.23 (1.99–2.48) | 1.47 (1.29–1.69) | <0.001 |
Anaemia at baseline | 77.2 | 90.1 | 2.69 (2.27–3.19) | 1.67 (1.36–2.05) | <0.001 |
Tuberculosis treatment at baseline | 34.0 | 45.5 | 1.62 (1.46–1.79) | 0.90 (0.78–1.04) | 0.140 |
PI base regimen | 0.2 | 0.6 | 3.26 (1.46–7.28) | 4.35 (1.22–15.49) | 0.023 |
Cotrimoxazole preventive therapy at baseline | 91.3 | 93.5 | 1.37 (1.12–1.67) | 1.12 (0.84–1.50) | 0.455 |
OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; SD: Standard deviation; PI: Protease inhibitor; Anaemia: Haemoglobin concentration <12 g/dL in women and <13 g/dL in men.